GlassScriptPhysician profile
Russell Earnest
NPI 1992817480
$3,185.46
in general payments reported to CMS, 2019-2025
27 companies · $780 in 2025
The $780 reported for 2025 was more than what 75% of Podiatrist providers received nationally (typical 2025 total: $260).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $277 · 2020: $150 · 2021: $445 · 2022: $511 · 2023: $529 · 2024: $494 · 2025: $780.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,795 · Education: $7.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,794.91 |
| Education | $7.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $514.98 | 2020-2023 | Krystexxa |
| Amgen INC. | $356.04 | 2024-2025 | Krystexxa |
| Paratek Pharmaceuticals, INC. | $305.74 | 2021-2025 | Nuzyra |
| Convatec INC. | $301.97 | 2023-2025 | |
| Pacira Pharmaceuticals Incorporated | $146.82 | 2022 | |
| Ani Pharmaceuticals, INC. | $143.88 | 2025 | Purified Cortrophin Gel |
| Melinta Therapeutics, LLC | $141.13 | 2019 | |
| Linvatec Corporation | $136.04 | 2024 | Biobrace 23mm, Colink Vallux |
| Kerecis Limited | $135.71 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Medtronic, INC. | $131.34 | 2025 | Inceptiv, Intellis Adaptivestim |
| Abbvie INC. | $124.17 | 2021-2022 | |
| Organogenesis INC. | $119.15 | 2020-2023 | Puraply |
| Smith+Nephew, INC. | $117.04 | 2021-2022 | |
| Kci USA, INC. | $108.66 | 2019 | |
| Bioventus LLC | $57.27 | 2020-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $54.10 | 2024-2025 | |
| Boston Scientific Corporation | $50.60 | 2024 | |
| Abbott Laboratories | $48.75 | 2023-2025 | Proclaim |
| Nevro Corp. | $31.94 | 2022 | |
| Grt US Holding, INC. | $31.48 | 2022 | |
| Merck Sharp & Dohme LLC | $27.65 | 2019 | |
| Anika Therapeutics, INC. | $21.12 | 2024 | Integrity, Toe Motion |
| Heron Therapeutics, INC. | $20.53 | 2021 | |
| Averitas Pharma INC. | $17.03 | 2025 | Qutenza |
| Hartmann USA, INC. | $14.81 | 2025 | Zetuvit Plus 10x10 P10 |
| Bsn Medical INC | $14.49 | 2022 | |
| Dynasplint Systems INC. | $13.02 | 2023 | Dynasplint |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Russell Earnest listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.